IP Library Granted Patent US 11,919,883
Granted Patent B2
US 11,919,883 · App. 17/462,909 · Granted Mar 5, 2024

Metalloenzyme inhibitor compounds

Inventors: Steven Sparks (Apex, NC); Christopher M. Yates (Raleigh, NC); Sammy R. Shaver (Chapel Hill, NC)
Assignee: Ji Xing Pharmaceuticals Hong Kong Limited
C07D403/04C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,919,883
App. No.
17/462,909
Granted
Mar 5, 2024
Kind
B2
Abstract

Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

Claims (46)

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof; wherein

A is N or CR 5 ;

W is N or CR 6 ;

X is N or CR 6 ;

Y is N or CR 6 ;

Z is N or CR 6 ;

provided that no more than two of W, X, Y, and Z are N;

R 1 is hydrogen, halogen, cyano, acyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, NR a R b , NHSO 2 R c , (CH 2 ) n NR a R b , (CH 2 ) n NHSO 2 R d , (CH 2 ) n NHCO 2 R d , CO 2 R e , COR f , (CH 2 ) n OR f , or CR e R f OH;

R 2 is hydrogen, halogen, cyano, acyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, NR a R b , NHSO 2 R c , CH 2 NR a R b , CH 2 NHSO 2 R d , CO 2 R e , COR f , CH 2 OR f , or CR e R f OH;

R 3 is hydrogen, halogen, cyano, acyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, NR a R b , NHSO 2 R c , (CH 2 ) n NR a R b , (CH 2 ) n NHSO 2 R d , CO 2 R e , COR f , (CH 2 ) n OR f , or CR e R f OH;

each n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

R 4 is cyclopropyl;

R 5 is hydrogen, alkyl, haloalkyl, heteroalkyl, or cycloalkyl;

each occurrence of R 6 is, independently, hydrogen, halogen, cyano, haloalkyl, alkyl, cycloalkyl, haloalkyl, alkoxy, haloalkoxy, alkylsulfonyl, or carboxyl; and

each occurrence of R a , R b , R c , R d , R e , and R f are, independently, hydrogen, acyl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxyalkyl, C(O)OC 1-6 alkyl, C(O)C 1-6 alkyl, a nitrogen protecting group when attached to a nitrogen atom, or an oxygen protecting group when attached to an oxygen atom; or R a and R b together with the atoms to which they are attached form a heterocycloalkyl ring; or R e and R f together with the atoms to which they are attached form a cycloalkyl ring.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen, halogen, cyano, alkyl, haloalkyl, alkoxy, NR a R b , or CH 2 NR a R b .

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen, halogen, cyano, alkyl, NR a R b , or haloalkyl; and R a and R b are, independently, hydrogen, alkyl, or heteroalkyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is alkyl or haloalkyl.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is haloalkyl.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 and R 3 are hydrogen.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 6 is, independently, hydrogen, halogen, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy or alkylsulfonyl.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 6 is, independently, hydrogen, halogen, or cyano.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is CR 5 and R 5 is hydrogen, C 1-4 alkyl or C 3-5 cycloalkyl.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is N.

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein no more than one of W, X, Y, and Z is N.

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein W, X, Y, and Z are each CR 6 .

13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is N.

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is N.

15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula I-b:

16. The compound of claim 15 , or a pharmaceutically acceptable salt thereof, wherein X is CR 6 .

17. The compound of claim 16 , or a pharmaceutically acceptable salt thereof, wherein X is CR 6 , wherein R 6 is halogen; and

each of W, Y, and Z is N or CR 6 , wherein each occurrence of R 6 is, independently, hydrogen, halogen, cyano, haloalkyl, alkyl, cycloalkyl, haloalkyl, alkoxy, haloalkoxy, alkylsulfonyl, or carboxyl.

18. The compound of claim 15 , or a pharmaceutically acceptable salt thereof, wherein Y is CR 6 .

19. The compound of claim 18 , or a pharmaceutically acceptable salt thereof, wherein Y is CR 6 , wherein R 6 is halogen; and

each of W, X, and Z is N or CR 6 , wherein each occurrence of R 6 is, independently, hydrogen, halogen, cyano, haloalkyl, alkyl, cycloalkyl, haloalkyl, alkoxy, haloalkoxy, alkylsulfonyl, or carboxyl.

20. The compound of claim 15 , or a pharmaceutically acceptable salt thereof, wherein X and Y are CR 6 .

21. The compound of claim 20 , or a pharmaceutically acceptable salt thereof, wherein each of X and Y are CR 6 , wherein each R 6 is halogen; and

each of W and Z is N or CR 6 , wherein each occurrence of R 6 is, independently, hydrogen, halogen, cyano, haloalkyl, alkyl, cycloalkyl, haloalkyl, alkoxy, haloalkoxy, alkylsulfonyl, or carboxyl.

22. The compound of claim 21 , or a pharmaceutically acceptable salt thereof, wherein each of W and Z is CR 6 , wherein each occurrence of R 6 is, independently, hydrogen, halogen, cyano, haloalkyl, alkyl, cycloalkyl, haloalkyl, alkoxy, haloalkoxy, alkylsulfonyl, or carboxyl.

23. The compound of claim 15 , or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen, halogen, cyano, alkyl, haloalkyl, alkoxy, NR a R b , or CH 2 NR a R b .

24. The compound of claim 15 , or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen, halogen, cyano, alkyl, NR a R b , or haloalkyl; and R a and R b are, independently, hydrogen, alkyl, or heteroalkyl.

25. The compound of claim 15 , or a pharmaceutically acceptable salt thereof, wherein R 1 is alkyl or haloalkyl.

26. The compound of claim 15 , or a pharmaceutically acceptable salt thereof, wherein R 1 is haloalkyl.

27. The compound of claim 15 , or a pharmaceutically acceptable salt thereof, wherein R 1 is fluoroalkyl.

28. A pharmaceutical composition comprising a compound or a pharmaceutical salt thereof of any one of claims 1 - 6 , 7 - 14 , and 15 - 27 , and a pharmaceutically acceptable carrier.

Assignments (12)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2026
From: CORXEL PHARMACEUTICALS LIMITED
To: CORXEL PHARMACEUTICALS, INC.
Reel/Frame 073958/0129 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2026
From: CORXEL PHARMACEUTICALS HONG KONG LIMITED
To: CORXEL PHARMACEUTICALS LIMITED
Reel/Frame 073958/0018 →
CHANGE OF NAME Recorded Mar 14, 2025
From: JI XING PHARMACEUTICALS HONG KONG LIMITED
To: CORXEL PHARMACEUTICALS HONG KONG LIMITED
Reel/Frame 070523/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: SELENITY THERAPEUTICS (BERMUDA), LTD.
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 066322/0622 →
CHANGE OF NAME Recorded Feb 1, 2024
From: VIAMET PHARMACEUTICALS (BERMUDA), LTD.
To: SELENITY THERAPEUTICS (BERMUDA), LTD.
Reel/Frame 066407/0406 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: SPARKS, STEVEN; YATES, CHRISTOPHER M.; SHAVER, SAMMY R.
To: VIAMET PHARMACEUTICALS (NC), INC.
Reel/Frame 066322/0468 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: VIAMET PHARMACEUTICALS (NC), INC.
To: VIAMET PHARMACEUTICALS (BERMUDA), LTD.
Reel/Frame 066322/0522 →
CORRECTION OF ERROR IN ASSIGNEE ADDRESS AS LISTED IN COVER SHEET PREVIOUSLY RECORDED AT REEL/FRAME 062691/0373 Recorded Jun 6, 2023
From: PHASEBIO PHARMACEUTICALS, INC.
To: JI XING PHARMACEUTICALS HONG KONG LIMITED
Reel/Frame 063873/0889 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2023
From: PHASEBIO PHARMACEUTICALS, INC.
To: JI XING PHARMACEUTICALS HONG KONG LIMITED
Reel/Frame 062691/0373 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2023
From: JMB CAPITAL PARTNERS LENDING, LLC
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 062376/0850 →
SECURITY INTEREST Recorded Oct 31, 2022
From: PHASEBIO PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 061601/0001 →
SECURITY INTEREST Recorded Oct 10, 2022
From: PHASEBIO PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 061367/0674 →
Continuity (4)
Division 16746098 · Jan 17, 2020
Division 15858015 · Dec 29, 2017
Provisional Application 62440199 · Dec 29, 2016
Related Publication 20220009907A1 · Jan 13, 2022